Herald Investment Management Ltd Takes Position in Simulations Plus, Inc. $SLP

Herald Investment Management Ltd purchased a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) during the third quarter, HoldingsChannel reports. The firm purchased 200,000 shares of the technology company’s stock, valued at approximately $3,016,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Tributary Capital Management LLC increased its holdings in shares of Simulations Plus by 214.7% during the third quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after acquiring an additional 775,704 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Simulations Plus by 25.3% during the second quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock worth $15,277,000 after buying an additional 176,747 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Simulations Plus by 3.1% in the second quarter. Geode Capital Management LLC now owns 397,851 shares of the technology company’s stock valued at $6,943,000 after buying an additional 12,003 shares in the last quarter. Stephens Investment Management Group LLC grew its holdings in shares of Simulations Plus by 46.3% during the third quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock valued at $5,920,000 after buying an additional 124,264 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in shares of Simulations Plus during the second quarter worth about $6,232,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SLP. KeyCorp reaffirmed a “sector weight” rating on shares of Simulations Plus in a research report on Wednesday, October 29th. BTIG Research lowered Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. TD Cowen restated a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Finally, Citigroup reissued a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of “Hold” and an average target price of $25.00.

Simulations Plus Trading Up 1.5%

NASDAQ:SLP opened at $12.29 on Friday. The firm’s 50 day moving average is $18.19 and its 200 day moving average is $16.57. Simulations Plus, Inc. has a 12 month low of $12.00 and a 12 month high of $37.67. The stock has a market capitalization of $247.64 million, a PE ratio of -3.84 and a beta of 1.12.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.05). The firm had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same quarter in the previous year, the firm earned $0.17 earnings per share. Research analysts predict that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.